SCHEMBL24310357

SCHEMBL24310357

CCc1c(Oc2ccccc2C)nc(NS(=O)(=O)c2cnn(C)c2)nc1-c1ccccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 7/20 0.41
▸ HTR7 P34969 7/20 0.41
▸ DRD2 P14416 3/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ THRB P10828 1/20 0.34
▸ HTR2A P28223 2/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ BRAF P15056 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ SLC22A12 Q96S37 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566856 1.00 HTR1A (0.41) HTR1AHTR7DRD2HTR6THRB
SCHEMBL26811477 0.93 HTR1A (0.39) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566471 0.93 HTR1A (0.40) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24310809 0.93 HTR1A (0.40) HTR1AHTR7DRD2HTR6THRB
SCHEMBL26811501 0.92 HTR1A (0.39) HTR1AHTR7KDM5AKMT2APIK3CD
SCHEMBL29566633 0.91 HTR1A (0.45) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL24310362 0.91 HTR1A (0.45) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL24309827 0.90 HTR1A (0.43) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566900 0.90 HTR1A (0.43) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566902 0.89 HTR1A (0.40) HTR1AHTR7KDM5AKMT2APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885DRD2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback